Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services National Institutes of Health
 SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) The quality, utility, and clarity of the information to be collected; and (4) The approaches used to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. *To Submit Comments and for Further Information:*
                         To obtain a copy of the data collection plans and instruments, submit comments in writing or request more information on the proposed project, contact: Kevin P. Conway, Ph.D., Deputy Director, Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 5185; or call non-toll-free number (301)-443-8755; or Email your request, including your address to: 
                        *PATHprojectofficer@mail.nih.gov.*
                         Formal requests for additional plans and instruments must be requested in writing. *Comment Due Date:*
                         Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. *Proposed Collection:*
                         Population Assessment of Tobacco and Health (PATH) Study—Third Wave of Data Collection—0925-0664-REVISION—National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), in partnership with the Food and Drug Administration (FDA). *Need and Use of Information Collection:*
                         This is a revision request (OMB 0925-0664, Exp. Date 9/30/2016) for the Population Assessment of Tobacco and Health (PATH) Study to conduct the third wave of data collection. The PATH Study is a large national longitudinal cohort study on tobacco use behavior and health among the U.S. household population of adults age 18 and older and youth ages 12 to 17. The PATH Study conducts annual interviews and collects biospecimens from adults to help inform the development, implementation, and evaluation of tobacco-product regulations by FDA in meeting its mission under the Family Smoking Prevention and Tobacco Control Act (TCA) to regulate tobacco products, including tobacco-product advertising, labeling, marketing, constituents, ingredients, and additives. The longitudinal design of the PATH Study provides it with the capacity to measure and report within-person changes and between-person differences in tobacco product use behaviors and health effects within the cohort over time. These data will help to inform regulatory decisions and actions by FDA and FDA's evaluations of associations between its regulations and tobacco use behaviors and health indicators in the population. OMB approval is requested for 3 years. There are no capital, operating, or maintenance costs to report. There are no costs to respondents other than their time. The total estimated annualized burden hours are 53,459. Estimated Annualized Burden Hours
Type of respondent and instrument
Number of 
                             respondents
Number of 
                             responses per  
                             respondent
Average burden per response 
                             (in hours)
Total annual 
                             burden hoursAdults—Adult respondents at Wave 1 or Wave 2—Extended Interview
25,692
1
1
25,692Adults—Wave 1 youth respondents who age up to adult cohort at Wave 3—Consent for Extended Interview
2,317
1
4/60
154Adults—Wave 1 youth respondents who age up to adult cohort at Wave 3—Extended Interview
1,738
1
68/60
1,970Adults—Wave 1 youth respondents who age up to adult cohort at Wave 3—Consent for Biological Samples
1,738
1
5/60
145Adults—Biospecimen Collection: Urine
13,703
1
10/60
2,284( print page 7620)Adults—Biospecimen Collection: Blood
869
1
18/60
261Adults—Tobacco Use Form
14,572
1
4/60
971Adults—Follow-up/Tracking Participant Information Form
27,430
2
8/60
7,315Youth—Youth respondents at Wave 1 or Wave 2—Extended Interview
9,515
1
32/60
5,075Youth—Shadow youth who age up to youth cohort at Wave 3—Assent for Extended Interview
2,420
1
3/60
121Youth—Shadow youth who age up to youth cohort at Wave 3—Extended Interview
1,912
1
42/60
1,338Adult—Youth respondents at Wave 1 or Wave 2—Parent Interview
9,705
1
14/60
2,265Adults—Parents of Shadow youth who age up to youth cohort at Wave 3—Parent Permission and Consent for Parent Interview
2,420
1
5/60
202Adults—Parents of Shadow youth who age up to youth cohort at Wave 3—Parent Interview
1,950
1
17/60
553Adults—Verification Interview
35,564
1
2/60
1,185Adults—Validation Interview
3,613
1
4/60
241Adults—Follow-up/Tracking Participant Information Form for Youth (completed by parents)
11,427
2
8/60
3,047Adults—Follow-up/Tracking Participant Information Form for sample Shadow youth (completed by parents)
2,401
2
8/60
640
 Dated: February 5, 2015. Genevieve deAlmeida-Morris, Project Clearance Liaison, National Institute on Drug Abuse, NIH.


[FR Doc. 2015-02832 Filed 2-10-15; 8:45 am] BILLING CODE 4140-01-P